Exploring the consequences of greater price transparency on the dynamics of pharmaceutical markets:
For some time, governments, stakeholders and civil society have been voicing the need for greater transparency in pharmaceutical pricing. The 2018 OECD report Pharmaceutical Innovation and Access to Medicines suggested that increased price transparency could promote public accountability, while pote...
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Weitere Verfasser: | |
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Paris
OECD Publishing
2022
|
| Schriftenreihe: | OECD Health Working Papers
no.146 |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Zusammenfassung: | For some time, governments, stakeholders and civil society have been voicing the need for greater transparency in pharmaceutical pricing. The 2018 OECD report Pharmaceutical Innovation and Access to Medicines suggested that increased price transparency could promote public accountability, while potentially delivering efficiencies to health systems by including economic considerations in coverage, treatment decisions and budget allocation. Despite this, precisely what should be made more transparent, and how greater transparency would affect the functioning of markets, have been poorly characterised. To help frame the policy debate, the OECD undertook an exploration of the potential consequences of greater price transparency on market dynamics. The work included a roundtable and a series of semi-structured interviews, with participation by 19 experts in pharmaceutical pricing, economics of pharmaceutical markets, competition, and law. With an extensive review of the current practice and relevant literature as a preface, this report presents the key findings from those consultations |
| Beschreibung: | 1 Online-Ressource (45 Seiten) |
| DOI: | 10.1787/c9250e17-en |
Internformat
MARC
| LEADER | 00000nam a22000001cb4500 | ||
|---|---|---|---|
| 001 | BV048675083 | ||
| 003 | DE-604 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 230125s2022 xx o|||| 00||| eng d | ||
| 024 | 7 | |a 10.1787/c9250e17-en |2 doi | |
| 035 | |a (ZDB-13-SOC)083002448 | ||
| 035 | |a (OCoLC)1369551067 | ||
| 035 | |a (DE-599)KEP083002448 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-188 |a DE-521 |a DE-1028 |a DE-573 |a DE-92 |a DE-898 |a DE-1049 |a DE-861 |a DE-91 |a DE-384 |a DE-473 |a DE-355 |a DE-20 |a DE-824 |a DE-29 |a DE-739 | ||
| 100 | 1 | |a Barrenho, Eliana |e Verfasser |4 aut | |
| 245 | 1 | 0 | |a Exploring the consequences of greater price transparency on the dynamics of pharmaceutical markets |c Eliana, Barrenho and Ruth, Lopert |
| 264 | 1 | |a Paris |b OECD Publishing |c 2022 | |
| 300 | |a 1 Online-Ressource (45 Seiten) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 490 | 0 | |a OECD Health Working Papers |v no.146 | |
| 520 | 3 | |a For some time, governments, stakeholders and civil society have been voicing the need for greater transparency in pharmaceutical pricing. The 2018 OECD report Pharmaceutical Innovation and Access to Medicines suggested that increased price transparency could promote public accountability, while potentially delivering efficiencies to health systems by including economic considerations in coverage, treatment decisions and budget allocation. Despite this, precisely what should be made more transparent, and how greater transparency would affect the functioning of markets, have been poorly characterised. To help frame the policy debate, the OECD undertook an exploration of the potential consequences of greater price transparency on market dynamics. The work included a roundtable and a series of semi-structured interviews, with participation by 19 experts in pharmaceutical pricing, economics of pharmaceutical markets, competition, and law. With an extensive review of the current practice and relevant literature as a preface, this report presents the key findings from those consultations | |
| 650 | 4 | |a Social Issues/Migration/Health | |
| 700 | 1 | |a Lopert, Ruth |4 ctb | |
| 856 | 4 | 0 | |u https://doi.org/10.1787/c9250e17-en |x Verlag |z kostenfrei |3 Volltext |
| 912 | |a ZDB-13-SOC | ||
| 943 | 1 | |a oai:aleph.bib-bvb.de:BVB01-034049569 | |
Datensatz im Suchindex
| _version_ | 1818896544641843200 |
|---|---|
| adam_text | |
| adam_txt | |
| any_adam_object | |
| any_adam_object_boolean | |
| author | Barrenho, Eliana |
| author2 | Lopert, Ruth |
| author2_role | ctb |
| author2_variant | r l rl |
| author_facet | Barrenho, Eliana Lopert, Ruth |
| author_role | aut |
| author_sort | Barrenho, Eliana |
| author_variant | e b eb |
| building | Verbundindex |
| bvnumber | BV048675083 |
| collection | ZDB-13-SOC |
| ctrlnum | (ZDB-13-SOC)083002448 (OCoLC)1369551067 (DE-599)KEP083002448 |
| discipline | Wirtschaftswissenschaften |
| discipline_str_mv | Wirtschaftswissenschaften |
| doi_str_mv | 10.1787/c9250e17-en |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>00000nam a22000001cb4500</leader><controlfield tag="001">BV048675083</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">230125s2022 xx o|||| 00||| eng d</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1787/c9250e17-en</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-13-SOC)083002448</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1369551067</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)KEP083002448</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-188</subfield><subfield code="a">DE-521</subfield><subfield code="a">DE-1028</subfield><subfield code="a">DE-573</subfield><subfield code="a">DE-92</subfield><subfield code="a">DE-898</subfield><subfield code="a">DE-1049</subfield><subfield code="a">DE-861</subfield><subfield code="a">DE-91</subfield><subfield code="a">DE-384</subfield><subfield code="a">DE-473</subfield><subfield code="a">DE-355</subfield><subfield code="a">DE-20</subfield><subfield code="a">DE-824</subfield><subfield code="a">DE-29</subfield><subfield code="a">DE-739</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Barrenho, Eliana</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Exploring the consequences of greater price transparency on the dynamics of pharmaceutical markets</subfield><subfield code="c">Eliana, Barrenho and Ruth, Lopert</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Paris</subfield><subfield code="b">OECD Publishing</subfield><subfield code="c">2022</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (45 Seiten)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">OECD Health Working Papers</subfield><subfield code="v">no.146</subfield></datafield><datafield tag="520" ind1="3" ind2=" "><subfield code="a">For some time, governments, stakeholders and civil society have been voicing the need for greater transparency in pharmaceutical pricing. The 2018 OECD report Pharmaceutical Innovation and Access to Medicines suggested that increased price transparency could promote public accountability, while potentially delivering efficiencies to health systems by including economic considerations in coverage, treatment decisions and budget allocation. Despite this, precisely what should be made more transparent, and how greater transparency would affect the functioning of markets, have been poorly characterised. To help frame the policy debate, the OECD undertook an exploration of the potential consequences of greater price transparency on market dynamics. The work included a roundtable and a series of semi-structured interviews, with participation by 19 experts in pharmaceutical pricing, economics of pharmaceutical markets, competition, and law. With an extensive review of the current practice and relevant literature as a preface, this report presents the key findings from those consultations</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Social Issues/Migration/Health</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lopert, Ruth</subfield><subfield code="4">ctb</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1787/c9250e17-en</subfield><subfield code="x">Verlag</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-13-SOC</subfield></datafield><datafield tag="943" ind1="1" ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-034049569</subfield></datafield></record></collection> |
| id | DE-604.BV048675083 |
| illustrated | Not Illustrated |
| index_date | 2024-07-03T21:23:47Z |
| indexdate | 2024-12-19T19:01:58Z |
| institution | BVB |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-034049569 |
| oclc_num | 1369551067 |
| open_access_boolean | 1 |
| owner | DE-188 DE-521 DE-1028 DE-573 DE-92 DE-898 DE-BY-UBR DE-1049 DE-861 DE-91 DE-BY-TUM DE-384 DE-473 DE-BY-UBG DE-355 DE-BY-UBR DE-20 DE-824 DE-29 DE-739 |
| owner_facet | DE-188 DE-521 DE-1028 DE-573 DE-92 DE-898 DE-BY-UBR DE-1049 DE-861 DE-91 DE-BY-TUM DE-384 DE-473 DE-BY-UBG DE-355 DE-BY-UBR DE-20 DE-824 DE-29 DE-739 |
| physical | 1 Online-Ressource (45 Seiten) |
| psigel | ZDB-13-SOC |
| publishDate | 2022 |
| publishDateSearch | 2022 |
| publishDateSort | 2022 |
| publisher | OECD Publishing |
| record_format | marc |
| series2 | OECD Health Working Papers |
| spelling | Barrenho, Eliana Verfasser aut Exploring the consequences of greater price transparency on the dynamics of pharmaceutical markets Eliana, Barrenho and Ruth, Lopert Paris OECD Publishing 2022 1 Online-Ressource (45 Seiten) txt rdacontent c rdamedia cr rdacarrier OECD Health Working Papers no.146 For some time, governments, stakeholders and civil society have been voicing the need for greater transparency in pharmaceutical pricing. The 2018 OECD report Pharmaceutical Innovation and Access to Medicines suggested that increased price transparency could promote public accountability, while potentially delivering efficiencies to health systems by including economic considerations in coverage, treatment decisions and budget allocation. Despite this, precisely what should be made more transparent, and how greater transparency would affect the functioning of markets, have been poorly characterised. To help frame the policy debate, the OECD undertook an exploration of the potential consequences of greater price transparency on market dynamics. The work included a roundtable and a series of semi-structured interviews, with participation by 19 experts in pharmaceutical pricing, economics of pharmaceutical markets, competition, and law. With an extensive review of the current practice and relevant literature as a preface, this report presents the key findings from those consultations Social Issues/Migration/Health Lopert, Ruth ctb https://doi.org/10.1787/c9250e17-en Verlag kostenfrei Volltext |
| spellingShingle | Barrenho, Eliana Exploring the consequences of greater price transparency on the dynamics of pharmaceutical markets Social Issues/Migration/Health |
| title | Exploring the consequences of greater price transparency on the dynamics of pharmaceutical markets |
| title_auth | Exploring the consequences of greater price transparency on the dynamics of pharmaceutical markets |
| title_exact_search | Exploring the consequences of greater price transparency on the dynamics of pharmaceutical markets |
| title_exact_search_txtP | Exploring the consequences of greater price transparency on the dynamics of pharmaceutical markets |
| title_full | Exploring the consequences of greater price transparency on the dynamics of pharmaceutical markets Eliana, Barrenho and Ruth, Lopert |
| title_fullStr | Exploring the consequences of greater price transparency on the dynamics of pharmaceutical markets Eliana, Barrenho and Ruth, Lopert |
| title_full_unstemmed | Exploring the consequences of greater price transparency on the dynamics of pharmaceutical markets Eliana, Barrenho and Ruth, Lopert |
| title_short | Exploring the consequences of greater price transparency on the dynamics of pharmaceutical markets |
| title_sort | exploring the consequences of greater price transparency on the dynamics of pharmaceutical markets |
| topic | Social Issues/Migration/Health |
| topic_facet | Social Issues/Migration/Health |
| url | https://doi.org/10.1787/c9250e17-en |
| work_keys_str_mv | AT barrenhoeliana exploringtheconsequencesofgreaterpricetransparencyonthedynamicsofpharmaceuticalmarkets AT lopertruth exploringtheconsequencesofgreaterpricetransparencyonthedynamicsofpharmaceuticalmarkets |